Navigation Links
Bioheart, Inc. Announces Financial Results for Second Quarter 2008
Date:7/30/2008

follow this mark.

-- On July 2, 2008, the Company announced it was added to the Russell Microcap Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2008.

-- On July 1, 2008 the Company's Board of Directors appointed Howard J. Leonhardt, Bioheart's co-founder, Chairman of the Board and Chief Technology Officer, to serve as Chief Executive Officer.

Revenues for the quarter ended June 30, 2008 were $16,786 compared to $194,609 in the second quarter of 2007. During the quarter, the Company also recognized $15,000 of development revenue for services performed under a clinical registry agreement. The Company reported a net loss for the second quarter of 2008 of $3.9 million, or $(0.27) per share, compared to a net loss of $2.8 million, or $(0.21) per share, for the same quarter last year. The Company ended the quarter with cash and cash equivalents totaling $1.9 million.

The increase in the Company's net loss in the second quarter of 2008 as compared to the second quarter of 2007 is primarily attributable to increased stock-based compensation and interest expense related to $10 million of debt incurred by the Company in June 2007.

Research and development expenses for the second quarter of 2008 were $1.5 million compared to $1.8 million in the second quarter last year. The primary focus of the Company's research and development activities during the quarter related to the MARVEL Trial. The MARVEL Trial is the largest clinical trial of its kind to date, investigating the use of autologous myoblasts to treat patients suffering from congestive heart failure. These myoblasts, adult stem cells that are precursors to muscle, are derived from the patient's own body. When injected into scar tissue within the heart wall, myoblasts have shown they are capable of engrafting in the damaged tissue and differentiating into mature muscle cells capable of augmenting cardiac function
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. to Transfer to Nasdaq Capital Market
6. Bioheart, Inc., Added to Russell Microcap Index
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. Announces Results of Annual Meeting
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportl...ort is available in its catalogue: ,, Brazil B..., http://www.reportlinker.com/p0165503/Brazil-...tml ,, Brazil Bioethanol Market Analysis and F...provides detailed analysis and forecasts of the gl...
(Date:11/24/2009)... The New York investment bank KTA ...EU) has agreed an AU$6.7 mil convertible note priv...The private placement was arranged by KTA Capital ... , New York (PRWEB) Novem...t bank KTA Capital, LLC ("KTA Capital") ...
(Date:11/24/2009)... Health care employment grew by ...only one to show consistent growth during the U.S....ls remain in trouble, and health systems are comin...el, instead of just administrators. , ...are employment continued growing in October despit...
(Date:11/24/2009)...EATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.an...pmentAuthority(OPDA)wererecentlyawarded$2millionby...ard(CERB)inaprivate/publicpartnershiptoconstructth...olnCounty,WA. ,, "Thisinvestmentwillsignificant...0greenjobstoLincolnCounty,"saidBlueMarbleEnergyCEO...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...lcers each year in the US, PRINCETON, N.J., March...), provider of advanced wound care products,announ... the clinical usage,of its newly released MEDIHONE...mum Honey presented at the annual American Profess...ld the second week in March in Forth,Worth, Texas,...
...aunch..., WAYLAND, Mass., March 20 Tourtellotte ...linical trials software, announces the,launch of i...rm for phase,II-IV studies. Trident,s unique param...of legacy IVRS technologies and promises to delive...nd ease-of-use to the straining,global clinical IV...
...nc., a,pioneer in drug discovery from marine micro...begun in a Phase 1b study evaluating the vascular,...h standard chemotherapy,in patients with non-small...ositive outcomes in a Phase 1 single-agent clinica...armacodynamics (PK/PD) and efficacy of NPI-2358,in...
Other Biology Technology:Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 2Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 3Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 4Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 3
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 1ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 3ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 4ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 5ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 6ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 7Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 1Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 2Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 3
...AMBRIDGE, Mass. (April 2, 2009) Whitehead Institu...ifiable prion proteins in yeast and have further c...f both beneficial and detrimental traits. , "The ...al are they evolved to be prions, or are they alw...," says Randal Halfmann, a research assistant in W...
...New diseases directly affect human survival and fo...bs. Leaf-cutting ants, one of a few groups of soci...t material to fertilize their underground fungal g... Smithsonian show that both the ants and their fun...t inside leaves, thus ensuring the health of their...
...AMBRIDGE, Mass.--Each year, hundreds of thousands ...rmic needles that penetrate too far under their sk...lleagues aims to prevent this from happening by ke...urely mechanical, is based on concepts borrowed fr... needle containing a filament that acts as a guide...
Other Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2MIT: Novel needle could cut medical complications 2
UltraClean GelSpin Kit from Mo Bio Laboratories, Inc.
Rabbit Complement Lyophilized Powder from Equitech-Bio
Rabbit Anti-Human Histone H3, phospho (Ser10 / Ser28) Polyclonal Antibody, Unconjugated from Lake Placid Biologicals
UltraClean GelSpin Kit from Mo Bio Laboratories, Inc.
Biology Products: